Can a biologic drug tame juvenile arthritis in kids?

NCT ID NCT06431750

Terminated Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal is to see how effective this treatment is in real-world settings, outside of a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (an injectable biologic that targets inflammation)
What this could lead to: If successful, this study could provide real-world evidence on how well secukinumab controls juvenile arthritis in children, potentially guiding better treatment decisions.
What could go wrong: As an observational study, it cannot prove cause and effect, and results may be influenced by other factors. The study is also limited to a specific age group and disease subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE ENTHESITIS-RELATED ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

JUVENILE IDIOPATHIC ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.